Tateishi M, Ishida T, Hamatake M, Fukuyama Y, Kodono S, Sugimachi K, Akazawa K
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Eur J Surg Oncol. 1994 Aug;20(4):461-6.
We examined 70 fresh frozen sections of primary non-small cell lung cancer using a monoclonal antibody for DNA polymerase alpha (POL alpha). The tumors were divided into two groups; those with more than 5% of POL alpha positive cells were designated as POL alpha (+), while those with less than 5% were POL alpha (-). POL alpha (+) tumors were obtained in 33 (47%) cases. The incidence of POL alpha (+) in male patients was statistically higher than in females (P < 0.01). The incidence also correlated with the T(tumor) status; T1 < T2, T1 < T4, with a significance (P < 0.05). Based on data on 70 patients, the 5-year survival rates of POL alpha (+) and POL alpha (-) were 36% and 63%, respectively (p < 0.05). In 48 patients with adenocarcinoma, the 5-year survival rates of POL alpha (+) and POL alpha (-) were 25% and 60%, respectively (P < 0.05). In addition, in 26 patients with a tumor size of less than 3 cm, the 5-year survival rates of POL alpha (+) and POL alpha (-) were 13% and 74%, respectively (P < 0.01). To compare the prognostic significance of the variables, a multivariate analysis was used to show significance for survival in POL alpha (p < 0.05). Our data show that in non-small cell lung cancer, POL alpha expression is associated with the extent of malignancy and survival. Therefore, POL alpha is considered to be a useful prognostic parameter.
我们使用针对DNA聚合酶α（POLα）的单克隆抗体检测了70份原发性非小细胞肺癌新鲜冰冻切片。肿瘤被分为两组；POLα阳性细胞超过5%的肿瘤被指定为POLα（+），而低于5%的则为POLα（-）。33例（47%）患者出现POLα（+）肿瘤。男性患者中POLα（+）的发生率在统计学上高于女性（P<0.01）。该发生率也与T（肿瘤）状态相关；T1<T2，T1<T4，具有显著性（P<0.05）。基于70例患者的数据，POLα（+）和POLα（-）的5年生存率分别为36%和63%（P<0.05）。在48例腺癌患者中，POLα（+）和POLα（-）的5年生存率分别为25%和60%（P<0.05）。此外，在26例肿瘤大小小于3 cm的患者中，POLα（+）和POLα（-）的5年生存率分别为13%和74%（P<0.01）。为了比较各变量的预后意义，采用多因素分析显示POLα对生存具有显著性（P<0.05）。我们的数据表明，在非小细胞肺癌中，POLα表达与恶性程度和生存相关。因此，POLα被认为是一个有用的预后参数。
